Curis | CRIS - Operating Expenses


Curis reported $11.52M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bayer EUR 10.04B 168M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
CSL USD 5.7B 2.82B Dec/2025
Curis USD 11.52M 2.5M Mar/2026
Eli Lilly USD 10.52B 496M Jun/2026
Exelixis USD 380.28M 20.8M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Novartis USD 10.2B 912M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Takeda JPY 1.02T 89.68B Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Verastem USD 63.57M 4.56M Mar/2026